<DOC>
	<DOCNO>NCT02460133</DOCNO>
	<brief_summary>This pilot study crucial determine whether treat individual high risk transmission re-infection impact HCV reinfection rate . It establish feasibility DAA treatment correction facility , well delineate underlie immune basis HCV cure reinfection .</brief_summary>
	<brief_title>Understanding HCV Reinfection Rates Incarcerated Population After Cure With Interferon Free HCV Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>An offender PEI Provincial Correction Centre enrollment time Male , 18 70 year age , inclusive , time screen Chronic HCV genotype 1 infection HCV infection , demonstrate positive HCV immunosorbant assay detectable HCV viral load No evidence decompensated liver disease ( refractory ascites , variceal bleed within 1 year , active hepatic encephalopathy ChildPugh score great 6 ) HIV negative Males must abstinent sexual intercourse , surgically sterile agree practice two effective form birth control list , throughout course study , start Study Day 1 7 month last dose study drug ( per local RBV label ) : Partner ( ) use IUD ( intrauterine device ) , Partner ( ) use oral , injected , implanted method hormonal contraceptive , Subject and/or partner ( ) use condom , contraceptive sponge , diaphragm spermicidal jelly cream . Subjects must able understand adhere study visit schedule protocol requirement Must voluntarily sign date inform consent form , approve Research Ethics Board prior initiation screening study specific procedure History severe , lifethreatening significant sensitivity drug Positive test result screen Hepatitis B surface antigen Prior therapy direct acting antiviral treatment HCV Evidence decompensated liver disease ( current past refractory ascites , variceal bleed within 1 year , active hepatic encephalopathy ) HIV positive screen test Unwilling follow 48 week treatment completion Use herbal supplement ( include milk thistle ) within 2 week 10 halflives respective supplement , whichever longer , prior first dose study drug HCV genotype perform screen indicate unable genotype coinfection HCV genotype Use medication contraindicate use study regimen Clinically significant abnormality , HCVinfection , base upon result medical history , physical examination , vital sign , laboratory profile make subject unsuitable candidate study opinion investigator Serum AlphaFetoprotein ( AFP ) &gt; 200 ng/mL screen Any cause liver disease chronic HCVinfection , include limited following : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Nonalcoholic steatohepatitis Drugrelated liver disease Screening laboratory analysis show follow abnormal laboratory result : ALT &gt; 5 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &gt; 5 × ULN Calculated creatinine clearance ( use CockcroftGault method ) &lt; 60 mL/min Albumin 25 g/L Prothrombin time/International normalize ratio ( INR ) &gt; 2.3 . Hemoglobin &lt; LLN Platelets &lt; 60,000 cell per mm3 Absolute neutrophil count ( ANC ) &lt; 1500 cells/μL Total bilirubin ≥ 51 umol/L History solid organ transplantation . Receipt investigational product within time period equal 10 halflives product , know , minimum 6 week prior study drug administration . Consideration investigator , reason , subject unsuitable candidate receive paritaprevir , dasabuvir , ombitasvir , ritonavir and/or RBV . Current enrollment another clinical study , prior enrollment study , previous exposure paritaprevir , ombitasvir , dasabuvir . Concurrent participation noninterventional , epidemiologic registry trial may permit approval principal investigator . The use colony stimulate factor , granulocyte colony stimulate factor ( GCSF ) erythropoietin within 2 month screen period . Uncontrolled clinically significant cardiac , respiratory ( except mild asthma ) , hepatic , gastrointestinal , hematologic psychiatric disease disorder , uncontrolled medical illness , unrelated hepatic disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>